| A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes | Cancer Cell | 2006 | 2.4K |
| Idelalisib and rituximab in relapsed chronic lymphocytic leukemia | New England Journal of Medicine | 2014 | 1.3K |
| Molecular biology of the androgen receptor | Journal of Clinical Oncology | 2002 | 729 |
| United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia | Journal of Clinical Oncology | 2001 | 690 |
| Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine | Journal of the National Cancer Institute | 2003 | 627 |
| Structure-based design of potent non-peptide MDM2 inhibitors | Journal of the American Chemical Society | 2005 | 543 |
| ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells | American Journal of Pathology | 2012 | 529 |
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors | EMBO Molecular Medicine | 2009 | 500 |
| Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: defining the stages of invadopodia formation and function | Cancer Research | 2006 | 458 |
| Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer | Clinical Cancer Research | 2013 | 443 |
| Bevacizumab plus ipilimumab in patients with metastatic melanoma | Cancer Immunology Research | 2014 | 428 |
| Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) | Cancer Epidemiology Biomarkers and Prevention | 2012 | 411 |
| Patient navigation: state of the art or is it science? | Cancer | 2008 | 401 |
| The matrix reorganized: extracellular matrix remodeling and integrin signaling | Current Opinion in Cell Biology | 2006 | 390 |
| Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling | Oncogene | 2003 | 370 |
| Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update | Journal of Clinical Oncology | 2015 | 363 |
| Mutational inactivation of STAG2 causes aneuploidy in human cancer | Science | 2011 | 329 |
| Matrix metalloproteinase inhibitors | Investigational New Drugs | 1997 | 327 |
| Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor | Journal of Biological Chemistry | 2007 | 321 |
| Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma | Nature Medicine | 2014 | 317 |
| Discovery of embelin as a cell-permeable, small-molecular weight inhibitor of XIAP through structure-based computational screening of a traditional herbal medicine three-dimensional structure database | Journal of Medicinal Chemistry | 2004 | 313 |
| An invasion-related complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular matrix degradation | Oncogene | 1999 | 311 |
| Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses | Journal of Clinical Oncology | 2000 | 307 |
| PD-1 as a potential target in cancer therapy | Cancer Medicine | 2013 | 306 |
| Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease | Journal of Biological Chemistry | 2000 | 299 |
